Xinda Biotech (01801.HK) first quarter product revenue exceeded 3.8 billion yuan, a year-on-year increase of over 50%.

The Zhixun Financial APP reported that Xinda Biotechnology (01801.HK) announced that in the first quarter of 2026, the company's product revenue exceeded 3.8 billion yuan, a year-on-year increase of over 50%. This strong momentum confirms the successful implementation of the company's "dual-drive" strategy. The company's leading position in the field of oncology is becoming increasingly significant, with rapid growth achieved after five tyrosine kinase inhibitors (TKIs) were included in the National Reimbursement Drug List (NRDL). At the same time, the comprehensive product line has become a strong emerging force driving the company's revenue growth, mainly due to the outstanding performance of core products such as Xin'ermei (Masitinib injection), Xingbile (Tolestimab injection), and Xingbimin (Toluximab N01 injection).